The U.S. Food and Drug Administration (FDA) has plenty of detractors. It’s accused of being sluggish and too cumbersome in approving new medications, especially vitally important anti-cancer medications.
Aggressive HER-2 positive metastatic breast cancer is difficult to treat. A recent study shows dual medication therapy offers new treatment options – and hope.
